Drugs survey in hospitals oF Córdoba city (Argentina)
DOI:
https://doi.org/10.31053/1853.0605.v62.n1.27653Keywords:
monitoring, adverse reactions for medicines, hospitalsAbstract
There were dcsigned Monitoring's study (FVG). centred on three Public Hospitais of Córdoba, seeking to detect Adverse Reactions for medicines. To such purpose there were realizeci forming courscs of human resources in FVG. FVG's cards were distributed, of own design, recovered then. For statistical calculation tflere was applied the INFO 4. 84 informecl cards were recovercd. The groups of involved medicines: they were: Antibioties (22%), cardiovascular (16%) aritiulcerous (10%), anxiolytics (8.75%), nonsteroidal anti-inflarnrnatory (8%). Onchologics (6%), anticonvulsants (3.75%), hypolypcmics (3.5%), sexual hormones (2.5%), hypoglycemlcs (2.5%), plasmatic cxpansors (2.5%). The organs affectcd by RAM were: Central Nervous Systeni (25%), skin (25%), gastrointestinal (17.5%). Blecds (7.5%), cardiovascular (7.5%), rcspiratory (7%), immune (6%), renal (4%). The analysis of imputability indicated: Definite RAM: 10 % - Probable RAM: 90%.
Downloads
References
Bateman DN: 'Aclverse reactions 1'. Br. Med. J. 1988; 296: 761-764.
Broche BB, Reid WD: 'Sorne pharmacological consequences of spccies variation in rates of rnetabolism", Federal Proceedings, 26, p 1062-1070, 1967.
Buenas prácticas de Investigación en Estudios de Farmacología Clínica. (ANMAT) N 5330/97.
Bulpitt CJ: "Randomised controlled
clinical trials", Martinus Nijhoff, The 1-lague,
1983
.
Finney DJ: "The design and logia of a monitor of drug use", Journal of Chronic Disease, 18, p 77-98. 1965.
Inman WHW: Monitoring for drug safety, págs. 36-37, MTP Press, Lancaster, 1980.
Karch FE, Lasagna, L: "Adverse drug reactions", Journal of the American Medical Association, 234(12), p 1236-1241. 1975.
S. Kessler DA: "Introducing MED WATCH. A new approach to reporting medication and device adverse effects and product problems. Jama 1993-269:2765-2768.
La Farmacovigilancia en España. Instituto de Salud Carlos III. Editores: E J. De Abajo, M. Madurga, J. E Olalla, R. Palop. Madrid 1992.
Laporte JR, Tognoni G: Principios de epidemiología del medicamento. Barcelona: Salvat, 1983. Laurence DR. Bennett PN: Clinical Pharmacology Ed Churchill Livingstone, Sed. 1980.
Lewis JA: "Ikst-marketingsurveifiance: how many patients?", Trends tu Pharrnaceutical Sciences, 2(4), p 93-94, 1981.
Naranjo C, Souich P Usoa EB: Métodos en farmacología clínica. OPS, 1992
Nuevas Perspectivas de la Ftirmacovigilancia en España y en la Unión Europea. Editores: Grupo iFAS. 1998.
Segarra Domeneche: "Necesidad de una terapéutica farmacológica racional". Rey. Clín. Esp. 1988: 183: 495-499.
Seoane MR, Bolaños R: "La nueva regulación argentina sobre buenas practices de investigación clínica". Cediquifa. Boletín N 38. Bs. As. Octubre 1998.
Stephens MDB: "Post marketing surveillance (PMS)", en Stephens, M. D. B.: The Detection of new adverse drug reactions, 2a cd., p 143-200, The Macmillan Press,
Basingtoke, 1988.
Vallvé C: Seguridad y Medicamentos, Barcelona: J.R. Prous, 1987.
Venning GR: "Identification of adverse reactions to new drug". "How were 18 important adverse reactions discovered and with what delays?". British Medical Journal, 286. p289-292, 365-368. 1983.
Walley T: "Rational prescribing in primary care. A new role for clinical pharmacologr" Br. J. Cline. Pharniac 1993:
36:11-12,..
Downloads
Published
Issue
Section
License
Copyright (c) 2021 Universidad Nacional de Córdoba
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The generation of derivative works is allowed as long as it is not done for commercial purposes. The original work may not be used for commercial purposes.
How to Cite
